1 February 2023
INFEX Therapeutics strengthens Board with appointment of Professor Colm Leonard as a Non-Executive Director
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the appointment of Professor Colm Leonard as a Non-Executive Director (“NED”) of Infex with immediate effect. Colm will also be chairing Infex’s...
26 January 2023
Healum wins NHS contract for patients at risk of CVD
Cardiovascular disease (CVD) is the single biggest condition where lives can be saved by the NHS over the next decade. There are 7.6 million people living with CVD in the UK, and Cardiovascular Disease is a leading cause of premature disability, mortality, and health...
10 January 2023
QV Bioelectronics raises £2m to develop revolutionary electric field therapy implant for brain tumour treatment
• £2M Pre-Series A financing raised from new and existing VCs. • The funds will facilitate the completion of pre-clinical studies and the further development of GRACE, a first-of-its-kind implanted medical device to treat brain tumour patients with electric field therapy...
9 January 2023
Monument Therapeutics announces first clinical study of MT1980 successfully meets all objectives
Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives … Monument Tx announce first-in-human clinical study for MT1980, a novel treatment for neuroinflammation...
5 January 2023
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has granted Qualified Infectious Disease Product (“QIDP”) designation to MET-X, the...
15 December 2022
Diabetes self-management app intellin® is a cost-effective solution for preventing diabetic foot ulcer recurrence
A study published in the journal Digital Health has found that the intellin® mHealth diabetes management platform is a cost-effective solution for managing and preventing the recurrence of diabetic foot ulcers. The study assessed patients at Salford Royal NHS Foundation...
14 December 2022
Pill Connect dispenser supports clinical trial for personalised Tuberculosis care
Pill Connect the smart dosing technology provider, has today announced the completion of its first clinical trial in collaboration with the UMCG KFF Clinical Pharmacy and Pharmacology in the Netherlands. Utilising Pill Connect’s Smart Dispenser technology, the study aimed...
29 November 2022
Extra £6.5m secured by tech firm which uses AI to speed up scientific discovery as it eyes US expansion
A tech spin-out from the University of Manchester, which uses AI to curate masses of biomedical data to help scientists speed up research and development, has secured a £6.5m boost. Biorelate has completed a Series A investment round led by Maven Capital Partners and YFM...
23 November 2022
Blueberry Therapeutics Ltd announces nomination of BB1511 for clinical development for the treatment of Atopic Dermatitis (Eczema)
Alderley Park, 22 November 2022 – Blueberry Therapeutics are pleased to announce that their novel cream formulation for the treatment of atopic dermatitis (BB1511) has been nominated for clinical development. This nomination decision was unanimous following review of...
21 November 2022
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the first subjects have been dosed in Phase I study in healthy volunteers evaluating the Company's lead drug candidate RESP-X, a new anti-virulence therapy to treat Pseudomonas aeruginosa (Pa)...